MedTrace Logo

Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients

NCT04041219 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-07

Study results available
· View outcomes & findings →

Summary

Researchers are trying to learn more about using sublingual (absorption under the tongue) tacrolimus in blood and marrow transplant patients.

Conditions

  • Immunosuppression
  • Stem Cell Transplant
  • Bone Marrow Transplant

Interventions

DRUG

Tacrolimus

Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.

DRUG

Tacrolimus

Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses

Sponsors & Collaborators

Principal Investigators

  • Heather May, Pharm. D., R. Ph. · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-17
Primary Completion
2019-10-08
Completion
2019-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04041219 on ClinicalTrials.gov